U.S. stock market update: Quoin Pharmaceuticals down 14.08%, cash flow crisis and FDA meeting fail to boost market confidence

U.S. Stock Market Midday Update Quoin Pharmaceuticals fell 14.08%. Based on recent key news: On March 26, Quoin Pharmaceuticals disclosed cash flow restrictions and going concern qualification issues in an SEC filing, which may affect the timing of trials and commercialization plans, increasing execution risks. This news led to a significant drop in stock price. Source: SEC announcement On March 25, Quoin Pharmaceuticals held a constructive meeting with the U.S. FDA, which expressed an open attitude towards the alternative Phase III design of QRX003, stating that a single Phase III study might be sufficient for U.S. approval. This news failed to boost market confidence, and the stock price continued to decline. Source: Company announcement On March 26, Quoin Pharmaceuticals' main product QRX003 is exploring treatments for various skin diseases. Despite a rich product line, concerns about its financial condition have intensified, putting pressure on the stock price. Source: Company announcement. The biopharmaceutical industry is facing funding pressures and regulatory challenges. Top Stocks by Industry Trading Volume AbbVie fell 0.68%, with increased trading volume. Based on recent key news: On March 27, AbbVie announced that it will present new research on its dermatology product portfolio at the 2026 American Academy of Dermatology Annual Meeting. This news may draw market attention to its R&D capabilities, leading to stock price fluctuations. On March 26, AbbVie's Allergan Aesthetics showcased 21 evidence-based electronic posters at the AMWC conference in Monaco, highlighting its scientific differentiation and leadership position. This may have boosted market confidence in its aesthetic products. On March 26, market analysis showed that AbbVie has had an average annual return of 13.85% over the past decade, which may attract the attention of long-term investors and impact stock performance. Dermatology research has drawn market attention, and the industry outlook is optimistic. Forte Pharma fell 4.39%. No significant news recently; trading is active, and capital flows are evident. Considering sector and industry trends, this stock shows significant volatility, and specific reasons need further observation. no_news Amgen fell 1.24%, with increased trading volume. Amgen fell 1.24%. No significant news recently; trading is active, and capital flows are evident. Considering sector and industry trends, this stock shows significant volatility, and specific reasons need further observation. no_news Top Stocks by Industry Market Capitalization Gilead Sciences fell 1.69%. Based on recent news, On March 25, Gilead Sciences announced the acquisition of Ouro Medicines for $2.175 billion, expanding its footprint in the autoimmune disease field. This move enhances Gilead's inflammation pipeline, but concerns about its short-term financial impact have led to a decline in stock price On March 25, Gilead Sciences acquired Arcellx for $780 million, aiming to enhance its long-term oncology prospects. Although this move demonstrates confidence in next-generation CAR T cell therapies, investors are concerned about integration risks and regulatory challenges, putting pressure on the stock price. On March 27, the global pharmaceutical industry faced pressure from the "patent cliff," with multinational pharmaceutical companies supplementing their innovation pipelines through mergers and acquisitions. Gilead's multiple acquisitions reflect this trend, but the market has doubts about its ability to successfully integrate and achieve expected returns, further impacting the stock price. The global pharmaceutical industry is under pressure from the patent cliff, with increased demand for innovation pipelines